Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target

François Richard; Maxim De Schepper; Marion Maetens; Sophia Leduc; Edoardo Isnaldi; Tatjana Geukens; Karen Van Baelen; Ha Linh Nguyen; Peter Vermeulen; Steven Van Laere; François Bertucci; Naoto Ueno; Luc Dirix; Giuseppe Floris; Elia Biganzoli; Christine Desmedt

doi:10.1016/j.breast.2023.01.010

Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target

François Richard, Maxim De Schepper, Marion Maetens, Sophia Leduc, Edoardo Isnaldi, Tatjana Geukens, Karen Van Baelen, Ha Linh Nguyen, Peter Vermeulen, Steven Van Laere, François Bertucci, Naoto Ueno, Luc Dirix, Giuseppe Floris, Elia Biganzoli, Christine Desmedt

Breast Medical Oncology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Inflammatory breast cancer (IBC) is a rare but aggressive subtype of breast cancer, mainly characterized using primary tumor samples. Here, using public datasets, we compared the genomic alterations in primary and metastatic samples from patients with metastatic IBC versus patients with metastatic non-IBC. We observed a higher frequency of AURKA amplification in IBC. We further showed that AURKA amplification was associated with increased AURKA mRNA expression, which we demonstrated was higher in IBC. Finally, higher protein expression of AURKA was associated with worse prognosis in patients with IBC. These findings deserve further investigation given the existence of AURKA-inhibitors.

Original language	English (US)
Pages (from-to)	476-480
Number of pages	5
Journal	Breast
Volume	69
DOIs	https://doi.org/10.1016/j.breast.2023.01.010
State	Published - Jun 2023

Keywords

AURKA-Inhibitors
Genomic alterations
Inflammatory breast cancer
Metastatic breast cancer

ASJC Scopus subject areas

Surgery
Oncology
Cancer Research

Access to Document

10.1016/j.breast.2023.01.010

Cite this

Richard, F., De Schepper, M., Maetens, M., Leduc, S., Isnaldi, E., Geukens, T., Van Baelen, K., Nguyen, H. L., Vermeulen, P., Van Laere, S., Bertucci, F., Ueno, N., Dirix, L., Floris, G., Biganzoli, E., & Desmedt, C. (2023). Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target. Breast, 69, 476-480. https://doi.org/10.1016/j.breast.2023.01.010

Richard, F, De Schepper, M, Maetens, M, Leduc, S, Isnaldi, E, Geukens, T, Van Baelen, K, Nguyen, HL, Vermeulen, P, Van Laere, S, Bertucci, F, Ueno, N, Dirix, L, Floris, G, Biganzoli, E & Desmedt, C 2023, 'Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target', Breast, vol. 69, pp. 476-480. https://doi.org/10.1016/j.breast.2023.01.010

@article{0a389356ab014864b343ff8d394e4b1f,

title = "Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target",

abstract = "Inflammatory breast cancer (IBC) is a rare but aggressive subtype of breast cancer, mainly characterized using primary tumor samples. Here, using public datasets, we compared the genomic alterations in primary and metastatic samples from patients with metastatic IBC versus patients with metastatic non-IBC. We observed a higher frequency of AURKA amplification in IBC. We further showed that AURKA amplification was associated with increased AURKA mRNA expression, which we demonstrated was higher in IBC. Finally, higher protein expression of AURKA was associated with worse prognosis in patients with IBC. These findings deserve further investigation given the existence of AURKA-inhibitors.",

keywords = "AURKA-Inhibitors, Genomic alterations, Inflammatory breast cancer, Metastatic breast cancer",

author = "Fran{\c c}ois Richard and {De Schepper}, Maxim and Marion Maetens and Sophia Leduc and Edoardo Isnaldi and Tatjana Geukens and {Van Baelen}, Karen and Nguyen, {Ha Linh} and Peter Vermeulen and {Van Laere}, Steven and Fran{\c c}ois Bertucci and Naoto Ueno and Luc Dirix and Giuseppe Floris and Elia Biganzoli and Christine Desmedt",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = jun,

doi = "10.1016/j.breast.2023.01.010",

language = "English (US)",

volume = "69",

pages = "476--480",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target

AU - Richard, François

AU - De Schepper, Maxim

AU - Maetens, Marion

AU - Leduc, Sophia

AU - Isnaldi, Edoardo

AU - Geukens, Tatjana

AU - Van Baelen, Karen

AU - Nguyen, Ha Linh

AU - Vermeulen, Peter

AU - Van Laere, Steven

AU - Bertucci, François

AU - Ueno, Naoto

AU - Dirix, Luc

AU - Floris, Giuseppe

AU - Biganzoli, Elia

AU - Desmedt, Christine

PY - 2023/6

Y1 - 2023/6

N2 - Inflammatory breast cancer (IBC) is a rare but aggressive subtype of breast cancer, mainly characterized using primary tumor samples. Here, using public datasets, we compared the genomic alterations in primary and metastatic samples from patients with metastatic IBC versus patients with metastatic non-IBC. We observed a higher frequency of AURKA amplification in IBC. We further showed that AURKA amplification was associated with increased AURKA mRNA expression, which we demonstrated was higher in IBC. Finally, higher protein expression of AURKA was associated with worse prognosis in patients with IBC. These findings deserve further investigation given the existence of AURKA-inhibitors.

AB - Inflammatory breast cancer (IBC) is a rare but aggressive subtype of breast cancer, mainly characterized using primary tumor samples. Here, using public datasets, we compared the genomic alterations in primary and metastatic samples from patients with metastatic IBC versus patients with metastatic non-IBC. We observed a higher frequency of AURKA amplification in IBC. We further showed that AURKA amplification was associated with increased AURKA mRNA expression, which we demonstrated was higher in IBC. Finally, higher protein expression of AURKA was associated with worse prognosis in patients with IBC. These findings deserve further investigation given the existence of AURKA-inhibitors.

KW - AURKA-Inhibitors

KW - Genomic alterations

KW - Inflammatory breast cancer

KW - Metastatic breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85147219717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147219717&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2023.01.010

DO - 10.1016/j.breast.2023.01.010

M3 - Article

C2 - 36717329

AN - SCOPUS:85147219717

SN - 0960-9776

VL - 69

SP - 476

EP - 480

JO - Breast

JF - Breast

ER -

Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this